BioCardia, Inc.
BCDA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000925741
In the last 90 days, BioCardia, Inc. insiders filed 10 open-market purchases and 0 sales; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding BioCardia, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 22 | 23 | +1 |
| Shares | 2.87M | 2.98M | +111.3K (+3.9%) |
| Value | $9.01M | $5.78M | −$3.23M (−35.9%) |
New holders (4)
Institutions that held BioCardia, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 56,419 | $109.0K | 0.01% |
| Two Sigma Securities, LLC | 21,196 | $41.0K | 0.01% |
| UBS Group AG | 5,813 | $11.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 2,200 | $4.00K | 0.00% |
Sold out (3)
Institutions that held BioCardia, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Renaissance Technologies LLC | 43,549 | $137.0K |
| Millennium Management LLC | 10,015 | $31.0K |
| US Bancorp | 3,612 | $11.0K |